NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are ...

Right now, Viking does not have any treatments that are formally approved by the FDA. Nevertheless, the company's lead ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Viking Therapeutics (VKTX) is up more than +5% after the company’s experimental pill, VK2735, showed weight loss in patients at higher doses with limited side effects. Air Transport Services Group ...

ByInvesting.com • Oct 25, 2024 Viking Therapeutics stock holds Buy rating with focus on upcoming oral VK2735 data at Obesity Week On Thursday, BTIG maintained a Buy rating on Viking Therapeutics ...

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...